Article

1 Iconography
Access to the text (HTML) Access to the text (HTML)
PDF Access to the PDF text
Advertising


Access to the full text of this article requires a subscription.
  • If you are a subscriber, please sign in 'My Account' at the top right of the screen.

  • If you want to subscribe to this journal, see our rates



Journal of the American Academy of Dermatology
Sous presse. Epreuves corrigées par l'auteur. Disponible en ligne depuis le mercredi 24 juillet 2013
Doi : 10.1016/j.jaad.2013.06.023
accepted : 13 June 2013
Sweet syndrome: Clinical presentation, associations, and response to treatment in 77 patients
 

Nicole M. Rochet, BS a, Rahul N. Chavan, MD, PhD a, Mark A. Cappel, MD a, David A. Wada, MD b, Lawrence E. Gibson, MD a,
a Departments of Dermatology at Mayo Clinic College of Medicine, Rochester, Minnesota 
b University of Utah, Salt Lake City, Utah 

Correspondence to: Lawrence E. Gibson, MD, Department of Dermatology, Mayo Clinic, 200 First St SW, Rochester, MN 55905.
Abstract
Background

Sweet syndrome is a neutrophilic dermatosis with cutaneous tender lesions that can be associated with malignancies, infections, systemic inflammatory disorders, and medications. Although numerous studies have described Sweet syndrome, few studies have systematically investigated Sweet syndrome.

Objective

We sought to describe characteristics and treatments of patients with Sweet syndrome and evaluate clinical differences depending on the underlying cause.

Methods

A retrospective study was conducted to identify patients with Sweet syndrome evaluated at Mayo Clinic from 1992 to 2010.

Results

Of 77 patients with Sweet syndrome (mean age of onset 57 years), 43 (56%) were male. Eighteen patients (23%) reported a preceding infection. A total of 41 (53%) patients were classified as having classic Sweet syndrome, 27 (35%) patients had malignancy-associated Sweet syndrome, and in 9 (12%) patients drug-induced Sweet syndrome was considered. In all, 21 patients had a hematologic malignancy or myeloproliferative/myelodysplastic disorder, whereas 6 patients had solid tumors. The mean hemoglobin level, in both male and female patients (P < .0443 and P < .0035, respectively), was significantly lower in malignancy-associated versus classic and drug-induced Sweet syndrome. Systemic corticosteroids were the most frequently used treatment (70%).

Limitations

This is a retrospective study and represents patients from a single academic center.

Conclusions

Sweet syndrome is a distinctive disorder with certain clinical and histologic characteristics, which usually has a complete response to systemic corticosteroids. It is important to evaluate Sweet syndrome patients who have laboratory evidence of anemia for an underlying malignancy.

The full text of this article is available in PDF format.

Key words : drug-induced Sweet syndrome, malignancy-associated Sweet syndrome, Sweet syndrome, treatment

Abbreviations used : MDS, MPD



 Funding sources: None.
 Conflicts of interest: None declared.
 Reprints not available from the authors.



© 2013  American Academy of Dermatology, Inc.@@#104156@@
EM-CONSULTE.COM is registrered at the CNIL, déclaration n° 1286925.
As per the Law relating to information storage and personal integrity, you have the right to oppose (art 26 of that law), access (art 34 of that law) and rectify (art 36 of that law) your personal data. You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted.
Personal information regarding our website's visitors, including their identity, is confidential.
The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.
Close
Article Outline